Literature DB >> 6715550

A radioimmunoassay to measure piretanide in human serum and urine.

W Heptner, S Baudner, E E Dagrosa, C Hellstern, R Irmisch, H Strecker, H Wissmann.   

Abstract

This paper describes a specific radioimmunological method for determining the diuretic agent piretanide (4 phenoxy-3-(1-pyrrolidinyl)-5-sulfamoyl benzoic acid) in human serum, plasma and urine. The antiserum was raised in rabbits against an immunogen of piretanide coupled to bovine serum albumin. The iodinated hydroxy derivative of piretanide was used as tracer. The separation of free and antibody-bound piretanide was performed by precipitating the antibody-tracer complex by polyethylene glycol. The limit of detection was 4 ng/ml. Studies on specificity showed less than 0.5% cross-reactivity of an identified metabolite. Interassay reproducibility showed an average coefficient of variation of 7.3%, the interassay variation was 5%. A recovery experiment yielded 100.9% recovery. There is good agreement between parallel determinations of piretanide by RIA and HPLC in both human serum and urine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6715550     DOI: 10.1080/01971528408062996

Source DB:  PubMed          Journal:  J Immunoassay        ISSN: 0197-1522


  7 in total

1.  The absorption of piretanide from the gastro-intestinal tract is site-dependent.

Authors:  D Brockmeier; H G Grigoleit; H Leonhardt
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Pharmacodynamics and urine pharmacokinetics of three doses of piretanide.

Authors:  B H Meyer; F O Müller; H G Grigoleit; E E Dagrosa
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of some newer diuretics.

Authors:  B Beermann; M Grind
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 4.  Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

5.  Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination.

Authors:  G Ruf; S Gera; H G Luus; D Trenk; N de la Rey; K Löffler; W Schulz; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Pharmacokinetics of high doses of piretanide in moderate to severe renal failure.

Authors:  C Marone; F C Reubi; M Perisic; W Lahn
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Pharmacokinetics of the loop diuretic piretanide in renal failure.

Authors:  U Walter; A Röckel; W Lahn; A Heidland; W Heptner
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.